

33. The antibody of Claim 31 wherein the antibody is a humanized form of said antibody.

34. The antibody of Claim 31 wherein the antibody is a chimeric form of said antibody.

35. A cell line which produces an antibody which binds to the same epitope on human lymphocytes as the antibody produced by the cell line deposited as ATCC HB 11423.

36. A process for producing an antibody comprising:

producing an antibody by culturing the cell line of Claim 35.

37. The antibody of Claim 31 wherein said antibody elicits alloantigen specific hyporesponsiveness.

38. A composition, comprising:

(a) an antibody which binds to the same epitope on human lymphocytes as the antibody produced by the cell line deposited as ATCC HB 11423; and

(b) a pharmaceutically acceptable carrier, wherein said antibody is present in said composition in an amount effective to inhibit a T-cell mediated immune response.

39. The composition of Claim 38 wherein the antibody is a monoclonal antibody.

40. The composition of Claim 39 wherein the antibody is a rat antibody.

41. The composition of Claim 39 wherein the antibody is a humanized form of said antibody.

42. The antibody of Claim 39 wherein the antibody is a chimeric form of said antibody.

43. The composition of Claim 38 wherein said antibody is present in said composition in an amount effective to elicit alloantigen specific hyporesponsiveness.

#### REMARKS

The above is a preliminary amendment to the continuation application of application Serial No. 08/472,281, filed June 7, 1995. Claims 1-29 have been cancelled without prejudice